Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine

Gemcitabine‐based therapy remains the mainstay of treatment for patients with biliary tract cancers (BTCs) with no second‐line treatment(s) established yet. Aberrant activation of the MAPK pathway in patients with BTC indicates its importance in BTC. Trametinib is a potent, highly selective, alloste...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikeda, Masafumi, Ioka, Tatsuya, Fukutomi, Akira, Morizane, Chigusa, Kasuga, Akiyoshi, Takahashi, Hideaki, Todaka, Akiko, Okusaka, Takuji, Creasy, Caretha L., Gorman, Shelby, Felitsky, Daniel J., Kobayashi, Mikiro, Zhang, Fanghong, Furuse, Junji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765304/
https://www.ncbi.nlm.nih.gov/pubmed/29121415
http://dx.doi.org/10.1111/cas.13438

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765304/
https://www.ncbi.nlm.nih.gov/pubmed/29121415
http://dx.doi.org/10.1111/cas.13438

Ejemplares similares